Media coverage about Adamas Pharmaceuticals (NASDAQ:ADMS) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamas Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.1131284595439 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the headlines that may have effected Accern’s analysis:

Adamas Pharmaceuticals (NASDAQ ADMS) traded up $0.72 during trading on Friday, reaching $28.41. The company’s stock had a trading volume of 855,507 shares, compared to its average volume of 498,093. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32. Adamas Pharmaceuticals has a 1 year low of $13.50 and a 1 year high of $29.29.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.03). During the same period in the previous year, the business posted ($0.66) earnings per share. Adamas Pharmaceuticals’s quarterly revenue was down 99.3% compared to the same quarter last year. equities analysts anticipate that Adamas Pharmaceuticals will post -3.87 EPS for the current fiscal year.

ADMS has been the subject of a number of recent research reports. Noble Financial restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. Cowen and Company set a $45.00 target price on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Mizuho reiterated a “buy” rating and set a $48.00 price objective (up from $26.00) on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 13th. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a research note on Sunday, September 17th. Finally, ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $42.00.

ILLEGAL ACTIVITY WARNING: “Adamas Pharmaceuticals (ADMS) Getting Somewhat Favorable Media Coverage, Report Shows” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.